Drug Profile
Gadopiclenol - Guerbet
Alternative Names: EluciremTM; G03277; P03277; VUEWAY; VuewayLatest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Guerbet
- Developer Bracco Imaging; Guerbet
- Class Diagnostic agents; Gadolinium-containing contrast agents; Macrocyclic compounds; Propylamines; Pyridines
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed CNS disorders
- Phase III Unspecified
- Phase II Liver cancer
Most Recent Events
- 11 Dec 2023 Registered for CNS disorders (Diagnosis, In adolescents, In children, In adults) in European Union (IV)
- 11 Dec 2023 Registered for CNS disorders (Diagnosis, In adolescents, In children, In adults) in Liechtenstein (IV)
- 11 Dec 2023 Registered for CNS disorders (Diagnosis, In adults, In adolescents, In children) in Iceland (IV)